How Immunotherapy Is Changing Cancer Treatment


Maurie Markman, MD

Was this helpful? (3)
Doctor Examining Patient Lymph Nodes

In the past, many patients with advanced cancers had limited treatment options. If removing the cancer surgically didn’t work, and then chemotherapy or radiation didn’t kill the cancer, patients were left with few choices.

Today, however, a type of treatment called immunotherapy, which uses our own immune systems to fight cancer cells, is offering effective results for these patients and changing how we think about cancer care.

The concept of using our own immune systems to fight cancer has been around for a long time. For the last century, doctors and researchers have been working to develop a way to harness the power of our own bodies in this fight. Specifically in the last 30 years, lots of research has focused on this concept, and today we are well on our way to understanding the best way to enhance our immune systems’ abilities to fight cancer. Now, a substantial percentage of cancer patients with an increasing number of cancer types are seeing an impact with new immunotherapies. Immunotherapies improve symptoms and quality of life, have few side effects, and, most importantly, extend survival—they’re changing the paradigm.

With certain cancer patients, immunotherapy can give people the chance to have a normal life.

2017 Healthgrades Operating Company, Inc. All rights reserved. May not be reproduced or reprinted without permission from Healthgrades Operating Company, Inc. Use of this information is governed by the Healthgrades User Agreement.

The History of Immunotherapy

In general, immunotherapy is a way to modify and activate the patient’s own immune system to fight foreign invaders and eliminate them. When you have a cold, your immune system identifies the invading cold cells and fights them off. However, we don’t see this exact process occur when the body tries to fight cancer cells. Experts first believed this was because the immune system wasn’t working hard enough, so for many years, patients were put on medications that helped their immune systems work harder. However, while this worked for a small percentage of patients, the majority didn’t benefit at all—plus the side effects were hard to tolerate.

In the late 1990s, a scientist named James Allison, Ph.D., theorized that the problem may not have anything to do with boosting the immune system. He found that the immune system was already quite stimulated in cancer patients; however, its ability to fight invaders was being blocked by cancer cells. This ability to “blockade” or “inhibit” the immune system from fighting is actually normal. When your immune system fights and destroys invaders, it releases molecules that shield your own tissues from these attacks. This way, the immune system’s army knows what to fight and what to protect. But Dr. Allison and his colleagues found that cancer cells use this strategy for their benefit. They use these molecules themselves to hide from the immune system, so immune cells don’t know to fight the cancer.

This discovery led to the development of one kind of immunotherapy, a class of drugs called checkpoint inhibitors, that block the cancer cells from hiding. This way, the immune system recognizes cancer as a foreign substance and destroys it.

Research has led to the development of several other types of immunotherapies, but today, checkpoint inhibitors are the leading type due to their success rates and low side effects.

The Impact of Checkpoint Inhibitors

Today, there are four checkpoint inhibitors approved by the U.S. Food and Drug Administration (FDA): ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq). These drugs treat many different types of cancer, mostly (but not always) when they’ve reached advanced stages. They’ve been shown to eliminate cancer from the body entirely in some cases, with results lasting years. Many patients are now living cancer-free five and even 10 years after starting treatment.

However, checkpoint inhibitors aren’t a magic bullet for all patients. Currently, they only work in 30 to 40% of patients. Our goal now is to find out why these therapies only work for some patients, and how to extend their effects. Lots of researchers are studying these questions. But for the patients who respond, immunotherapies give them a second chance at life.

The Future of Immunotherapy

Initially, checkpoint inhibitors were approved only to treat patients with advanced cancers. However, some have now been approved as a first-line treatment for melanoma, and more approvals are sure to come. Additionally, experts are looking at the benefits of combining two immunotherapies at once—we’re seeing longer-lasting cancer-free survival in more patients, but also more difficult side effects.

It’s an exciting time for cancer research. Immunotherapies are being studied to treat every type of cancer—even the rarest tumor types. And patients are comforted by the concept of using their own bodies to help fight their cancers. It’s a powerful idea, to know that something within yourself is going to fight this foreign thing called cancer. And immunotherapy is a powerful treatment that we’re learning more about every day.

THIS CONTENT DOES NOT PROVIDE MEDICAL ADVICE. This content is provided for informational purposes and reflects the opinions of the author. It is not a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of a qualified healthcare professional regarding your health. If you think you may have a medical emergency, contact your doctor immediately or call 911.

Maurie Markman

Maurie Markman, MD

Maurie Markman, MD, is a nationally-renowned oncologist who serves as President of Medicine and Science at Cancer Treatment Centers of America. View his Healthgrades profile >

This content is selected and managed by the Healthgrades editorial staff and is brought to you by an advertising sponsor.

This content is created or selected by the Healthgrades editorial team and is funded by an advertising sponsor. The content is subject to the Healthgrades medical review process for accuracy, balance and objectivity. The content is not edited or otherwise influenced by the advertisers appearing on this page except with the possible suggestion of the broad topic area. For more information, read the HealthGrades advertising policy.


Healthgrades logo

Get the FREE "Fighting Cancer With Immunotherapy" email series.  You will receive six emails with EXCLUSIVE content on immunotherapy.


Which of the following conditions are you MOST interested in?

By clicking "Get Started" I agree to Healthgrade's privacy policy  and user agreement.
Was this helpful? (3)

© 2017 Healthgrades Operating Company, Inc. All rights reserved. May not be reproduced or reprinted without permission from Healthgrades Operating Company, Inc. Use of this information is governed by the Healthgrades User Agreement.

Your opinion matters!

Please fill out this short, 1-3 minute survey about Advances in Immunotherapy. Your answers are anonymous and will not be linked to you personally.

The survey will appear at the end of your visit.

Thank you!

A survey will be presented to you after you finish viewing our Advances in Immunotherapy content.

You Might Also Like

Share via Email